FORSTEO Receives Approval For Glucocorticoid-Induced Osteoporosis Treatment
European Commission has approved Eli Lilly and Company's new indication for FORSTEO for the treatment of osteoporosis associated with sustained, systemic glucocorticoid therapy in women and men at increased risk for fracture.